Literature DB >> 25116245

[Osteogenesis imperfecta].

M Salzmann1, C Krohn, N Berger.   

Abstract

BACKGROUND: Osteogenesis imperfecta (OI) is the most common genetic disease of bone and is characterized by fragile bones and growth disorders of varying severity. Most cases of OI are inherited autosomal dominant and caused by a mutation in the collagen type I gene. DIAGNOSTICS: Indications for OI are bone fragility, stunted growth, scoliosis, skull deformities, blue sclera, loss of hearing, dentinogenesis imperfecta and increased laxity of ligaments and skin. In most cases it is possible to make a clinical diagnosis but a skin biopsy or genetic testing can be useful; however, negative results for these tests do not exclude OI. THERAPY: Therapy must be carried out in a multidisciplinary team and includes conservative (e.g. physiotherapy, rehabilitation programs and orthopedic aids), operative (e.g. intramedullary stabilization procedures) and pharmaceutical (e.g. biphosphonates and growth hormones) procedures. PROGNOSIS: The prognosis depends on the type of OI and ranges from normal life expectations for type 1 patients up to up to perinatal mortality for type II patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25116245     DOI: 10.1007/s00132-013-2229-3

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  32 in total

Review 1.  Classification of Osteogenesis Imperfecta revisited.

Authors:  F S Van Dijk; G Pals; R R Van Rijn; P G J Nikkels; J M Cobben
Journal:  Eur J Med Genet       Date:  2009-10-28       Impact factor: 2.708

2.  Osteogenesis imperfecta. Radiographic classification, natural history, and treatment of spinal deformities.

Authors:  D A Hanscom; R B Winter; L Lutter; J E Lonstein; B A Bloom; D S Bradford
Journal:  J Bone Joint Surg Am       Date:  1992-04       Impact factor: 5.284

Review 3.  Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Ann Med       Date:  2005       Impact factor: 4.709

Review 4.  Heritable diseases of collagen.

Authors:  D J Prockop; K I Kivirikko
Journal:  N Engl J Med       Date:  1984-08-09       Impact factor: 91.245

5.  Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.

Authors:  Chia-Hsuan Lin; Yin-Hsiu Chien; Shinn-Forng Peng; Wen-Yu Tsai; Yi-Ching Tung; Cheng-Ting Lee; Chun-Ching Chien; Wuh-Liang Hwu; Ni-Chung Lee
Journal:  Pediatr Neonatol       Date:  2014-01-31       Impact factor: 2.083

6.  Levothyroxine treatment in pediatric benign thyroid nodules.

Authors:  Andrea Corrias; Alessandro Mussa; Malgorzata Wasniewska; Maria Segni; Alessandra Cassio; Mariacarolina Salerno; Roberto Gastaldi; Maria Cristina Vigone; Milva Bal; Patrizia Matarazzo; Giovanna Weber; Filippo De Luca
Journal:  Horm Res Paediatr       Date:  2010-12-07       Impact factor: 2.852

7.  A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.

Authors:  L A Dimeglio; L Ford; C McClintock; M Peacock
Journal:  J Pediatr Endocrinol Metab       Date:  2005-01       Impact factor: 1.634

Review 8.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 9.  Osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

10.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.